Livmoniplimab, formerly designated MHG-8 or ARGX-115, represents a novel antibody intended for treating multiple cancer diseases. Its progression journey has involved a focused approach, initially directed on the mechanism of action, which blocks programmed cell death protein 1, a critical checkp

Tidutamab, a novel therapeutic, has been sparking substantial excitement in the oncology. Its journey commenced by focusing on a LAP target, a essential element believed to implicated in cancer hibernation and later progression. Initial clinical studies demonstrated encouraging findings, particul

Apoptosis, also recognized as programmed cell death, plays a vital role in maintaining tissue homeostasis. Dysregulation of apoptosis has been implicated in various pathologies, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, modulating apoptotic pathways repres